Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsNewsAboutContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

News

Baricitinib

(Olumiant®)

Olumiant®

Drug updated on 3/28/2024

Dosage FormTablet (oral; 1 mg, 2 mg, 4 mg)
Drug ClassJanus kinase inhibitors
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • For the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Baricitinib (Olumiant) is used for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers.
  • A review of 33 Systematic Reviews / Meta-Analyses documents provides comprehensive insights into baricitinib's efficacy, safety profile, and comparison with other Janus kinase inhibitors and different medications in treating rheumatoid arthritis.
  • In DMARD-naive patients with RA, baricitinib showed significantly higher remission rates compared to methotrexate; it ranked second after upadacitinib based on surface under the cumulative ranking curve probabilities for achieving remission.
  • Adverse effects such as increased odds of acne were noted across clinical practices and trials involving JAK inhibitors including baricitinib which had an odds ratio (OR) of 4.96 for incidence of acne following use.
  • Real-world evidence highlighted that baricitinib has high drug persistence rates comparable or equal to anti-tumor necrosis factor drugs, indicating its effectiveness outside controlled conditions like randomized controlled trials.
  • There are gaps in literature regarding targeted monotherapy tapering strategies in RA especially among patients looking to reduce medication where treatments like baricitniv are being explored necessitating further studies on dose adjustment and treatment sustainability.
  • In managing COVID-19 hospital admissions, usage of Barictininb resulted in a notable reduction in mortality risk suggesting a potential role beyond just rheumatoid arthritis management.
  • Compared against other JAK inhibitors as well as biological DMARDs and conventional synthetic DMARDs, baricinitnab demonstrated comparable efficacy rates but unique considerations based on dosage, patient demographics, and previous treatment history need be taken into account.

Product Monograph / Prescribing Information

Document TitleYearSource
Olumiant (baricitinib) Prescribing Information.2022Lilly USA, LLC, Indianapolis, IN

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis. 2023Pharmacology
Janus Kinase Inhibitors and Adverse Events of Acne: A Systematic Review and Meta-Analysis. 2023JAMA Dermatology
Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis. 2023Rheumatology and Therapy
The Gap in Knowledge about Tapering Targeted Therapy being used as Monotherapy in Rheumatoid Arthritis: A Systematic Review. 2023Current Rheumatology Reviews
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.2022The Lancet
JAK inhibitors and COVID-19.2022Journal for the ImmunoTherapy of Cancer
Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis.2022Expert Review of Anti-Infective Therapy
Efficacy and safety of immunomodulators in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials.2022Infectious Diseases and Therapy
The efficacy and safety of Janus kinase inhibitors for patients with COVID-19: a living systematic review and meta-analysis.2022Frontiers in Medicine
Janus kinase inhibitors for the treatment of COVID-19. 2022Cochrane Database of Systematic Reviews
The efficacy and safety of JAK inhibitors for alopecia areata: a systematic review and meta-analysis of prospective studies.2022Frontiers in Pharmacology
Therapeutic and anti-inflammatory effects of baricitinib on mortality, ICU transfer, clinical improvement, and CRS-related laboratory parameters of hospitalized patients with moderate to severe COVID-19 pneumonia: a systematic review and meta-analysis.2022Expert Review of Respiratory Medicine
Effectiveness and safety of baricitinib in patients with alopecia areata: a systematic review and meta-analysis of randomized controlled trials.2022Current Medical Research and Opinion
Systemic immunomodulatory treatments for atopic dermatitis update of a living systematic review and network meta-analysis.2022JAMA Dermatology
Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis.2022Dermatologic Therapy
Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors.2022Journal of the European Academy of Dermatology & Venerology
Baricitinib for the management of sars-cov-2-infected patients: a systematic review and meta-analysis of randomised controlled trials.2022Canadian Journal of Infectious Diseases and Medical Microbiology
Efficacy and safety of baricitinib for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis of randomized clinical trials.2022Clinical and Experimental Pharmacology and Physiology
Efficacy and safety of different doses of baricitinib for rheumatoid arthritis: a bayesian network meta-analysis.2022Medicine
Comparative efficacy and safety of peficitinib versus tofacitinib and baricitinib for treatment of rheumatoid arthritis: a systematic review and network meta-analysis. 2021Rheumatlogy and Therapy
Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis. 2021Therapeutic Advances in Musculoskeletal Disease
Current jakinibs for the treatment of rheumatoid arthritis: a systematic review. 2021Inflammopharmacology
Effect of disease modifying anti-rheumatic drugs on major cardiovascular events: a meta-analysis of randomized controlled trials.2021Scientific Reports
Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. 2021Modern Rheumatology
Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. 2021Rheumatic and Musculoskeletal Disease Open
Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider.2021Annals of the Rheumatic Diseases
The use of Janus kinase inhibitors in hospitalized patients with COVID-19: systematic review and meta-analysis. 2021Clinical Epidemiology and Global Health
Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: a systematic review and meta-analysis of randomized controlled trials. 2021Elsevier Public Health Emergency Collection
Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis.2020Mayo Clinic Proceedings
Clinical review report: baricitinib (Olumiant).2019CADTH
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.2019Rheumatology
Janus kinase inhibitors for rheumatoid arthritis: effectiveness and value.2019ICER
Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.2018Clinical Rheumatology
Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: a systematic review.2018Advances in Therapy
Risk of adverse drug events observed with baricitinib 2 mg versus baricitinib 4 mg once daily for the treatment of rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.2018BioDrugs

Clinical Practice Guidelines

Document TitleYearSource
Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence Taskforce.2022Medical Journal of Australia
Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline.2022European Respiratory Journal
Therapeutics and COVID-19.2022World Health Organization
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. 2021Annals of the Rheumatic Diseases
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.2020Annals of the Rheumatic Diseases